JP2006512398A5 - - Google Patents

Download PDF

Info

Publication number
JP2006512398A5
JP2006512398A5 JP2004565744A JP2004565744A JP2006512398A5 JP 2006512398 A5 JP2006512398 A5 JP 2006512398A5 JP 2004565744 A JP2004565744 A JP 2004565744A JP 2004565744 A JP2004565744 A JP 2004565744A JP 2006512398 A5 JP2006512398 A5 JP 2006512398A5
Authority
JP
Japan
Prior art keywords
composition
bladder
transduction enhancer
luminal surface
transduction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004565744A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006512398A (ja
Filing date
Publication date
Priority claimed from US10/327,869 external-priority patent/US7459154B2/en
Application filed filed Critical
Publication of JP2006512398A publication Critical patent/JP2006512398A/ja
Publication of JP2006512398A5 publication Critical patent/JP2006512398A5/ja
Withdrawn legal-status Critical Current

Links

JP2004565744A 2002-12-26 2003-12-24 膀胱上皮内へのウイルスの形質導入の増強のための方法および試薬 Withdrawn JP2006512398A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/327,869 US7459154B2 (en) 2002-12-26 2002-12-26 Methods and reagents for the enhancement of virus transduction in the bladder epithelium
PCT/US2003/041379 WO2004060303A2 (en) 2002-12-26 2003-12-24 Methods and reagents for the enhancement of virus transduction in the bladder epithelium

Publications (2)

Publication Number Publication Date
JP2006512398A JP2006512398A (ja) 2006-04-13
JP2006512398A5 true JP2006512398A5 (enExample) 2007-02-15

Family

ID=32680762

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004565744A Withdrawn JP2006512398A (ja) 2002-12-26 2003-12-24 膀胱上皮内へのウイルスの形質導入の増強のための方法および試薬

Country Status (9)

Country Link
US (7) US7459154B2 (enExample)
EP (1) EP1583502A4 (enExample)
JP (1) JP2006512398A (enExample)
KR (1) KR20050088231A (enExample)
CN (1) CN1753618A (enExample)
AU (1) AU2003299972C1 (enExample)
CA (1) CA2510903A1 (enExample)
NZ (1) NZ540732A (enExample)
WO (1) WO2004060303A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459154B2 (en) * 2002-12-26 2008-12-02 Cell Genesys, Inc. Methods and reagents for the enhancement of virus transduction in the bladder epithelium
US20050059613A1 (en) * 2003-07-08 2005-03-17 Bahram Memarzadeh Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium
KR20070121644A (ko) * 2005-01-14 2007-12-27 유리젠, 인코포레이티드 하부 요로 치료용 키트 및 개선된 조성물
WO2008033543A2 (en) 2006-09-14 2008-03-20 Bahram Memarzadeh Halogenated alkyl di- and trisaccharides, pharmaceutical formulations, diagnostic kits and methods of treatment
CN102695520A (zh) * 2008-05-27 2012-09-26 昂科利蒂克斯生物科技公司 调节间隙压力与溶瘤病毒的递送和分布
SG10201500015TA (en) * 2010-01-12 2015-02-27 Vascular Biogenics Ltd Methods of producing adenovirus vectors and viral preparations generated thereby
DE102011085501A1 (de) * 2011-10-31 2013-05-02 Söring GmbH Elektrochirurgievorrichtung
ES2994611T3 (en) * 2015-10-19 2025-01-27 Cg Oncology Inc Methods of treating solid or lymphatic tumors by combination therapy
PL3426271T3 (pl) 2016-03-10 2025-11-24 Cg Oncology, Inc. Sposoby leczenia guzów litych terapią skojarzoną
JP2020516590A (ja) 2017-04-14 2020-06-11 コールド ジェネシス, インコーポレイテッド 膀胱癌の治療方法
WO2020143221A1 (zh) * 2019-01-07 2020-07-16 四川安可康生物医药有限公司 增强系统免疫应答的免疫溶瘤病毒组合药物及其应用
CN115996940A (zh) * 2020-07-01 2023-04-21 免疫医疗有限责任公司 用于纯化生物治疗剂的洗涤剂和方法
CN113717953B (zh) * 2021-08-05 2024-07-26 北京舜雷科技有限公司 一种减毒黄病属病毒在溶瘤中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US169138A (en) * 1875-10-26 Improvement in folding lounges
JPH01245159A (ja) * 1988-03-28 1989-09-29 Gen Corp:Kk ニューカッスル病ウィルス抗体の検出用プレート及び抗原ウィルスの可溶化方法
US5369095A (en) 1990-02-14 1994-11-29 Alcon Laboratories, Inc. Compositions and method comprising substituted glycosides as mucus membrane permeation enhancers
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
US5525519A (en) * 1992-01-07 1996-06-11 Middlesex Sciences, Inc. Method for isolating biomolecules from a biological sample with linear polymers
US5368844A (en) 1992-12-16 1994-11-29 Colgate Palmolive Company Antiplaque, antigingivitis, anticaries oral composition
EP0865239B1 (en) * 1995-12-08 2001-10-24 Kao Corporation Germicidal composition
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US20020169138A1 (en) * 1997-10-24 2002-11-14 Southern Research Institute Delivery vehicles for bioactive agents and uses thereof
US6855549B1 (en) * 1998-11-23 2005-02-15 The University Of Iowa Research Foundation Methods and compositions for increasing the infectivity of gene transfer vectors
ATE419338T1 (de) 2000-03-24 2009-01-15 Cell Genesys Inc Menschliche zellspezifische urotheliale regulatorische sequenzen der transkription des uroplakins, dessen vektoren und verwendungsverfahren
US6911200B2 (en) 2000-03-24 2005-06-28 Cell Genesys, Inc. Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
IL139708A0 (en) * 2000-11-15 2002-02-10 Amiel Gilad Process of decellularizing biological matrices and acellular biological matrices useful in tissue engineering
AUPR894201A0 (en) * 2001-11-19 2001-12-13 Women's And Children's Hospital Respiratory delivery for gene therapy and lentiviral delivery particle
US7459154B2 (en) * 2002-12-26 2008-12-02 Cell Genesys, Inc. Methods and reagents for the enhancement of virus transduction in the bladder epithelium

Similar Documents

Publication Publication Date Title
JP2006512398A5 (enExample)
JP2007518683A5 (enExample)
JP2004525865A5 (enExample)
JP2004527525A5 (enExample)
JP2004510001A5 (enExample)
JP2007535327A5 (enExample)
JP2002530368A5 (enExample)
JP2009539740A5 (enExample)
JP2010518128A5 (enExample)
JP2004532509A5 (enExample)
JP2011522531A5 (enExample)
CN1191266C (zh) 治疗炎症应答的组合物
WO2007041071A2 (en) Oligonucleotide analogues incorporating 5-aza-cytosine therein
ES2175722T3 (es) Procedimiento de epoxidacion que utiliza catalizadores de plata soportados pretratados con cloruro organico.
JP2004509219A5 (enExample)
JP2004526302A5 (enExample)
JP2010535424A5 (enExample)
CN107216242A (zh) 一种铁催化氧化烷基芳香族化合物合成芳醛、芳酮和芳酯的方法
JP2009530853A5 (enExample)
JP2004528261A5 (enExample)
JP2002529478A5 (enExample)
JP2006500309A5 (enExample)
Biscans et al. Direct Synthesis of Partially Modified 2′‐O‐Pivaloyloxymethyl RNAs by a Base‐Labile Protecting Group Strategy and their Potential for Prodrug‐Based Gene‐Silencing Applications
JP2005526041A5 (enExample)
JP2023136725A5 (enExample)